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Insulin-degrading enzyme (IDE) is responsible for the degradation of a number of hormones
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and peptides, including insulin and amyloid b (Ab). Genetic studies have linked IDE to both
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type 2 diabetes and Alzheimer’s disease. Despite its potential importance in these diseases,
relatively little is known about the factors that regulate the activity and function of IDE.
Protein S-nitrosylation is now recognized as a redox-dependent, cGMP-independent signal-
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ing component that mediates a variety of actions of nitric oxide (NO). Here we describe a

Insulysin

mechanism of inactivation of IDE by NO. NO donors decreased both insulin and Ab

Proteasome

degrading activities of IDE. Insulin-degrading activity appeared more sensitive to NO

Amyloid-b

inhibition than Ab degrading activity. IDE-mediated regulation of proteasome activity

Type 2 diabetes mellitus

was affected similarly to insulin-degrading activity. We found IDE to be nitrosylated in

Alzheimer’s disease

the presence of NO donors compared to that of untreated enzyme and the control compound. S-nitrosylation of IDE enzyme did not affect the insulin degradation products
produced by the enzyme, nor did NO affect insulin binding to IDE as determined by
cross-linking studies. Kinetic analysis of NO inhibition of IDE confirmed that the inhibition
was noncompetitive. These data suggest a possible reversible mechanism by which inhibition of IDE under conditions of nitrosative stress could contribute to pathological disease
conditions such as Alzheimer’s disease and type 2 diabetes.
Published by Elsevier Inc.

1.

Introduction

Type 2 diabetes (T2DM) and Alzheimer’s disease (AD) share a
number of common features, including insulin resistance and
the presence of subacute, chronic inflammation [1]. Chronic

inflammation results in increased expression of the inducible
isoform of nitric oxide synthase (iNOS), leading to heightened
production of nitric oxide (NO) [2,3]. Increased iNOS is
associated with a prolonged, exaggerated production of NO,
and circulating levels of nitrite and nitrate (an indirect

* Corresponding author at: Research Service (151), Omaha Veterans Affairs Medical Center, 4101 Woolworth Avenue, Omaha, NE 68105,
United States. Tel.: +1 402 995 3032; fax: +1 402 449 0604.
E-mail address: fghamel@unmc.edu (F.G. Hamel).
Abbreviations: Ab, amyloid-beta; DSS, disuccinimydyl suberate; IDE, insulin-degrading enzyme; iNOS, inducible nitric oxide synthase;
KFC, potassium ferricyanide; LLVY, succinyl-leu-leu-val-tyr-7-amido-4-methyl coumarin; LSTR, boc-leu-ser-thr-arg-7-amido-4-methyl
coumarin; MMTS, methyl methanethiolsulfonate; NAP, N-acetylpenicillamine; NEM, N-ethylmalemide; NO, nitric oxide; PAPA-NONOate,
(Z)-1-[N-3-aminopropyl]-N-(n-propyl)amino]diazen-1-ium-1,2-dolate; SNAP, S-nitroso-N-acetylpenicillamine; SNP, sodium nitroprusside;
sulfo-NONOate, disodium (E)-1-sulfonatodiazen-1-ium-1,2-diolate; TCA, trichloroacetic acid.
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measurement of NO production) are increased in patients with
T2DM relative to healthy individuals [1,4].
The actions of NO can be classified as cGMP-dependent
actions (such as those related to vascular dilation) or as
reactive nitrogen species-mediated (independent of the
actions of cGMP). The cGMP-independent effects are often
mediated by nitrosative posttranslational modifications, such
as S-nitrosylation, and are thought to play a role in
pathological responses, including insulin resistance [5]. Snitrosylation involves the covalent attachment of a NO moiety
to protein sulfhydryls and is increased in the skeletal muscle
of patients with T2DM [4]. Insulin signaling molecules, such as
the insulin receptor, insulin receptor substrate-1 and Akt/PKB,
are S-nitrosylated in the skeletal muscle of obese, diabetic
mice [6]. Disruption of the iNOS gene has been shown to
preserve insulin sensitivity and prevent hyperinsulinemia in
mice with diet-induced insulin resistance [7,8]. iNOS gene
disruption also results in decreased formation of amyloid b
(Ab) plaques in a mouse model of AD [9]. Therefore, a
substantial body of research indicates the overproduction of
NO plays a role in the development of both T2DM and AD.
Insulin-degrading enzyme (IDE, insulysin, insulinase, EC
3.4.24.56), a zinc metalloproteinase, is the primary enzymatic
mechanism for intracellular insulin degradation, and appropriate IDE function is important for the preservation of insulin
sensitivity [10]. The Goto-Kakizaki rat, an animal model of
T2DM, contains mutations in the IDE gene and exhibits
elevated blood glucose and insulin levels [11]. Studies
conducted using the IDE knockout mouse have shown the
mice to be glucose intolerant and hyperinsulinemic, supporting the concept that IDE is important in the maintenance of
normal blood glucose and insulin levels [12]. Human genetic
studies have linked genetic polymorphisms in the IDE gene to
an increased risk for insulin resistance and T2DM [1,2]. In
addition, IDE is involved in the degradation of Ab in the brain,
and IDE hypofunction has been shown to contribute to the
accumulation of Ab plaques in AD [3,7].
Despite the potential importance of IDE, relatively little has
been published on its metabolic control. Ubiquitin, a peptide
similar in size (8.5 kDa) to insulin, has been shown to inhibit
insulin degradation by IDE, most likely in a competitive
manner [13,14]. The small molecule ATP has also been shown
to have effects on IDE. Camberos et al. showed ATP inhibited
insulin degradation [15]. However, it has also been reported
that ATP can increase degradation of small peptides by IDE,
while having little effect on insulin metabolism [16,17].
Whatever the effect on insulin degradation, ATP does induce
a conformational change in IDE [16]. We have shown that IDE
activity is inhibited non-competitively by select free fatty
acids and their coenzyme A thioesters [18]. IDE has been
shown to be sensitive to hydrogen peroxide, which could act
by affecting cysteine residues [19]. It has long been known that
IDE is sensitive to sulfhydryl modifying reagents [20–22]. There
are 13 cysteines in the predominately expressed form of IDE,
including one at the active site. However, it was not known
which of these was responsible for the sulfhydryl sensitivity. A
recent paper has identified three cysteines, C178, C812 and
C819 as the amino acid responsible for most of the sensitivity
[23]. These cysteines may be susceptible to nitrosylation.
Since, as noted above, increased NO production has been
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shown to have negative effects on insulin sensitivity, we chose
to examine the effect of NO on IDE activity and function. In this
study, we show that NO inhibits IDE-mediated degradation of
two IDE substrates, insulin and Ab, and that IDE-mediated
regulation of the proteasome is affected. The inhibition is
likely a result of S-nitrosylation. This demonstrates another
potential pathway by which increased iNOS may contribute to
the pathology of diabetes and Alzheimer’s disease, and
represents a potential therapeutic target for the treatment
of these diseases.

2.

Materials and methods

2.1.

Chemicals

NO donors S-nitroso-N-acetylpenicillamine (SNAP), sodium
nitroprusside (SNP), and (Z)-1-[N-3-aminopropyl]-N-(n-propyl)amino]diazen-1-ium-1,2-dolate (PAPA-NONOate), control
compound, disodium (E)-1-sulfonatodiazen-1-ium-1,2-diolate
(sulfo-NONOate), fluorogenic proteasome substrates succinylleu-leu-val-tyr-7-amido-4-methyl coumarin (LLVY) and bocleu-ser-thr-arg-7-amido-4-methyl coumarin (LSTR)), methyl
methanethiolsulfonate (MMTS), and disuccinimydyl suberate
(DSS) were purchased from Sigma (St. Louis, MO). Potassium
ferricyanide (KFC) and N-acetylpenicillamine (NAP) were
purchased from Fisher Scientific (Pittsburg, PA). 125I-human
recombinant insulin and 125I-b-amyloid were purchased from
Phoenix Pharmaceuticals (Burlingame, CA). EZ-link biotinHPDP (N-(6-(biotinamido)hexyl)-30 -(20 -pyridyldithio)-propionamide and neutravidin-agarose beads were purchased from
Pierce Biotechnology (Rockford, IL). Polyclonal anti-IDE antibody was purchased from Chemicon (Billerica, MA). All other
chemicals were of at least reagent grade.

2.2.

Enzyme preparation

Male Sprague-Dawley rats were maintained and used in
accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals, under a protocol
approved by the Subcommittee of Animal Studies and the
Research and Development Committee of the Omaha Veterans Affairs Medical Center. Insulin-degrading enzyme/proteasome was prepared from rat muscle or liver by
ultracentrifugation and ammonium sulfate precipitation,
similar to that described previously [20].

2.3.
Transfection, expression, and purification of
recombinant 6-Histidine labeled insulin-degrading enzyme
Human embryonic kidney (HEK) 293T cells were grown and
maintained in DMEM (high glucose)+10% FBS, 5% CO2. Cells
were transfected with pCMV 6-Histidine FLAG-labeled human
IDE using a calcium phosphate-mediated method modified
from Sambrook and Russell [24]. Cells were lysed in NETN buffer
(20 mM Tris–Cl (pH 8.0), 100 mM NaCl, 0.5% Nonidet P-40,
aprotinin, leupeptin, pepstatin, sodium orthovanadate, sodium
fluoride, and PMSF), and clarified by centrifugation. Lysate was
diluted in nickel binding buffer (20 mM sodium phosphate,
500 mM NaCl, 10 mM imidazole, pH 7.4), applied to a nickel
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affinity column (His GraviTrap, GE Healthcare), washed, and
bound proteins eluted with buffer containing 500 mM imidazole. The fractions with the highest insulin-degrading activity
were dialyzed against 50 mM HEPES-buffered saline + 1 mM
CaCl2 overnight and stored in 50% glycerol/HEPES-buffered
saline + 1 mM CaCl2 at 20 8C until assayed.

2.4.

Insulin degradation

The degradation of 125I-insulin and 125I-b-amyloid was measured by the trichloroacetic acid (TCA) solubility method. SNAP
was initially solubilized in DMSO and diluted with 100 mM Tris–
Cl, pH 7.4, with a final concentration of DMSO of <0.2% DMSO in
the assay (v/v). This concentration of DMSO had no effect on
enzyme activity (data not shown). SNP and KFC were solubilized
in the assay buffer (100 mM Tris–Cl). An aliquot of rat enzyme
was preincubated with increasing concentrations of NO donor
(SNP, SNAP, and PAPA-NONOate), control compound (KFC,
SNAP(ox), NAP, or sulfo-NONOate), or ascorbate [1  103 M] for
1 h at 37 8C, after which 125I-insulin or 125I-b-amyloid was added
and incubated an additional 15 min. The reaction was stopped
by addition of 0.5% (final) BSA and 10% (final) TCA. The samples
were centrifuged and the supernatant and pellet counted using
a g-counter, with data expressed as percent degradation relative
to untreated enzyme. Substrate incubated without enzyme was
subtracted as background solubility.

2.5.

2.7.

HPLC analysis of insulin degradation products

Rat liver IDE was incubated with the NO donors for 1 h at 37 8C
in 100 mM Tris–Cl buffer. Treated and untreated enzymes
were then incubated with approximately 5  105 cpm 125Iinsulin for 5 min at 37 8C and applied directly to a DuPont
Zorbax C-8 (4.6 mm  25 cm; 6 mm particle diameter) HPLC
column, similar to previously described [27]. Fractions (0.5 mL)
of the eluate were collected and analyzed using a g-counter to
determine the elution profile of radioactivity.

2.8.
Covalent cross-linking of
degrading enzyme

125

I-insulin to insulin-

Proteasome activity

The degradation of fluorogenic peptide substrates LLVY and
LSTR was used as measures of the chymotrypsin-like and
trypsin-like activities of the proteasome, respectively. Aliquots of rat muscle enzyme preparation were incubated with
varying concentrations of NO donors, control compounds,
ascorbate [1  103 M] in a 96-well black plate at 37 8C for 1 h.
LLVY or LSTR was added (13 mM final concentration), and
fluorescence measurements (ex/em: 355/460 nm) were taken
at 30, 60, 90, and 120 min. Data are expressed as the rate of
change in fluorescence units and normalized with respect to
the activity of untreated enzyme.

2.6.

(25 mM HEPES (pH 7.7) 1% SDS, 0.1 mM EDTA, 10 mM neocuproine) with two volumes of neutralization buffer (20 mM
HEPES (pH 7.7), 100 mM NaCl, 1 mM EDTA 0.5% Triton X-100),
and Neutravidin-agarose beads in order to select for biotinylated (i.e. ‘nitrosylated’) proteins. Samples were incubated with
the Neutravidin-agarose beads overnight at 4 8C and the beads
washed five times with neutralization buffer. Proteins bound to
the beads were eluted by heating with Laemmli SDS-PAGE
loading buffer (100 mM Tris, 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) glycerol, pH 6.8, b-mercaptoethanol, 10%
(w/v)). Proteins were resolved on SDS-polyacrylamide gels,
transferred to polyvinylidene fluoride (PVDF) membranes, and
probed for IDE using a polyclonal IDE antibody.

Biotinylation of NO-donor treated enzyme

Protein modifications were visualized using a biotinylation
method adapted from Jaffrey et al. [25,26]. Enzyme from rat
muscle or liver was treated with NO donors for 2 h at 37 8C to
maximize adduction. After treatment, samples were acetone
precipitated to remove any remaining NO donor and resuspendend in HEN buffer (250 mM HEPES (pH 7.7) 150 mM NaCl, 1%
Nonidet P-40, 1 mM EDTA, 20 mM MMTS, 0.1 mM neocuproine,
1 mM PMSF, 80 uM carmustine). One volume of MMTS buffer
(25 mM HEPES (pH 7.7) 5% SDS, 0.1 mM EDTA, 20 mM MMTS,
10 uM neocuproine) was added and the sample incubated at
50 8C for 30 min with frequent vortexing. Samples were acetone
precipitated to remove any MMTS and resuspended in HPDP
buffer (25 mM HEPES (pH 7.7) 1% SDS, 0.1 mM EDTA, 10 mM
neocuproine, 5 mM sodium ascorbate, 0.2 mM EZ-link HPDPbiotin). Samples were incubated in HPDP buffer for 1 h at room
temperature, and then acetone precipitated to remove the
biotinylating agent. Samples were resuspended in HENS buffer

Partially purified enzyme prepared from rat skeletal muscle or
liver was incubated with HEPES-buffered saline (140 mM NaCl,
1.5 mM Na2HPO42H2O, 50 mM HEPES, pH 7.4) and SNAP for 1 h
at 37 8C. After the treatment, SNAP was removed by
centrifugation in a Centricon Ultracel 50. Enzyme was
incubated with 2 ng of 125I-insulin (approximately
1  106 cpm) for 30 min at 4 8C. After the incubation, 1 mM
DSS (in DMSO) was added and incubated an additional 40 min
on ice, and the reaction stopped by the addition of 1 M Tris–Cl
(pH 7.4). Samples were mixed with 2 Laemmli SDS-PAGE
loading buffer, heated for 4 min at 100 8C, and electrophoresed
on a 7.5% SDS-polyacrylamide gel. The gels were stained with
Coomassie blue, dried, and scanned using an Amersham
Molecular Dynamics STORM 820 Phosphorimager.

2.9.

Measurement of NO release by donors

NO release by the donors used in the experiments was
measured by quantitation of total nitrate/nitrite (final products of NO decomposition) using 2,3-diaminonaphthalene
(DAN) (Nitrate/Nitrite Fluorometric Assay Kit; Cayman Chemical). Samples with enzyme were incubated with and
without NO donors for 1 h at 37 8C and then filtered through
a 10 kDa MWCO filter. Remaining nitrate in the solution was
converted to nitrite, total nitrite was determined by reaction
with DAN, and fluorescence was measured at 365/410–460 nm
(excitation/emission).

2.10.

Data analysis

Results are expressed as mean  S.E.M. Data were analyzed
using the Prism statistical software (v.4, GraphPad Software,
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San Diego). Significance was determined by one-way ANOVA
with Dunnett’s multiple comparison tests.

3.

Results

Fig. 1 shows the effect of NO donors and control compounds
on the insulin-degrading activity of IDE. Fig. 1a shows the
inhibition of insulin degradation with the addition of the NO
donor, SNP. SNP inhibits insulin degradation by 50% at the
highest concentration tested (1  103 M). KFC, a compound
structurally similar to SNP, but not an NO donor, had
relatively little effect. The treatment of the enzyme with
both SNP and ascorbate [1  103 M] had an increased
inhibitory effect on insulin degradation. Ascorbate alone
[1  103 M] had no effect on insulin degradation (data not
shown). Fig. 1b shows the concentration-dependent inhibitory effect of the NO donor, SNAP. However, SNAP combined
with ascorbate [1  103 M] did not have an effect on insulindegrading activity that was substantially different from that
of SNAP alone, and the control compound, SNAP(ox) had no
effect. Fig. 1c shows that the NO donor, PAPA-NONOate,
significantly inhibited insulin degradation up to 70%, while
sulfo-NONOate had no effect.
Since NO likely adducts IDE, we examined the kinetics of
the reaction to classify the type of inhibition. SNP release of NO
is dependent on the presence of light and/or reducing agents,
so we chose SNAP as the NO donor because it likely releases
NO spontaneously under our assay conditions. Analysis of the
nature of IDE inhibition by NO donors by Michaelis–Menten
plot confirmed that the inhibition by NO donors is noncompetitive. The data in Fig. 2 show the classic pattern of
noncompetitive inhibition, with the Km being similar for all
the concentrations of SNAP tested (mean 7.6  1.5 nM), while
the velocity of the reaction decreased with increasing SNAP
concentrations.
IDE degrades Ab as well as insulin, and we examined the
effect of the NO donors, SNAP, SNP, and PAPA-NONOate on
IDE-mediated degradation of Ab. First, we examined the
specificity of our partially purified enzyme preparation
toward Ab degradation. Competitive inhibition of the
substrate with insulin resulted in nearly complete inhibition
of Ab degradation (data not shown). We also studied the
effect of IDE inhibitors that are known to inhibit insulin
degradation. Fig. 3a shows that 1,10-phenanthroline, a
zinc chelator, inhibited Ab degradation significantly at
1  104 M, and this inhibition reached nearly 90% at
1  103 M. Irreversible sulfhydryl modification by N-ethylmalemide (NEM) also significantly inhibited Ab. The serine
protease inhibitor, PMSF, had no effect on Ab degradation.
We conclude that IDE was the major enzyme degrading
Ab in our preparation. We then examined the effect of NO
on IDE-mediated degradation of its substrate, Ab. Fig. 3b
shows that SNAP significantly inhibited Ab degradation by
25% at a concentration of 1  103 M. A control compound
for SNAP, N-acetylpenicillamine (NAP), did not inhibit Ab
degradation. SNP and PAPA-NONOate also inhibited Ab
degradation significantly, but their respective control
compounds (KFC and Sulfo-NONOate) did not exhibit an
effect.

Fig. 1 – 125I-Insulin degradation by IDE enzyme in the
presence of NO donor compounds. Partially purified rat
IDE enzyme was treated with increasing concentrations of
NO donor compounds with and without ascorbate
[1 T 10S3 M] and assessed for insulin-degrading activity.
(a) Curve fit of insulin degradation with SNP (&),
SNP + ascorbate (&), and control compound, KFC (^). (b)
Curve fit of enzyme treated with SNAP (*),
SNAP + ascorbate (*), and the control compound,
SNAP(ox) (~). (c) Insulin degradation curve fit of PAPANONOate (!) and sulfo-NONOate (T). NEM (grey bars) is
shown for reference. All graphs represent the
mean  S.E.M. of four independent experiments. *P < 0.05,
**P < 0.01.
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Table 1 – Nitric oxide release by NO donors.
Treatment
SNAP
PAPA-NONOate
SNP

Donor compound
(mM)
100
1000
1000

Nitrate/nitrite
(mM)
1.08  0.12
13.9  2.10
0.45  0.15

Measurement of NO release by SNAP, PAPA-NONOate and SNP
using fluorometric nitrate/nitrite quantitation. Background levels
of total nitrate/nitrite were subtracted (mean  S.E.M. of three
independent experiments).

Fig. 2 – Kinetic analysis of the inhibition of insulin
degradation by IDE enzyme in the presence of the NO
donor, SNAP. Partially purified IDE enzyme was incubated
with 125I-labeled insulin without NO donor treatment (&),
and treated with SNAP ([3 T 10S6 M] (5), [3 T 10S5 M] (*),
[3 T 10S4 M] (&)) and increasing concentrations of
unlabeled insulin. Enzyme activity was measured by the
generation of TCA-soluble 125I-insulin fragments and
expressed as picomoles of insulin degraded over 15 min
per microgram of enzyme. IDE was noncompetitively
inhibited by SNAP.

Our laboratory has shown that insulin will decrease the
chymotrypsin- and trypsin-like activities of the proteasome
when it is isolated in a complex with IDE. We tested whether
NO donors would have an effect on this inhibition. Fig. 4a
shows the inhibitory effect of insulin on chymotrypsin-like
activity, which is similar to that previously published [28]. In
the in vitro rat enzyme preparation containing the isolated IDE
and proteasome complex, the addition of SNAP inhibited the
chymotrypsin- and trypsin-like (Fig. 4a and b). The control,
oxidized NO donor, SNAP(ox), had no effect. SNP inhibition of

both proteasomal activities was only significant at 1  103 M,
but the addition of ascorbate increased the inhibitory capacity
of SNP toward the chymotrypsin-like activity (Fig. 4c and d).
Unlike SNAP(ox), the control compound KFC inhibited the
chymotrypsin- and trypsin-like activities 50% at a concentration of 1  103M.
The concentration of NO release in our assay conditions
was measured indirectly by fluorometric determination of
total nitrate and nitrite in the solution (Table 1). For NO donors
SNAP and PAPA-NONOate, the level of NO released was
approximately 100 times less than the concentration of
applied donor compound, with measurements in the mM
range. A similar trend was seen with the NO donor, SNP, with
1000 mM of compound releasing less than 0.5 mM of NO. Thus,
similar levels of enzyme inhibition are seen with similar NO
concentrations, regardless of the donor used.
The ability of NO donors to induce S-nitrosylation of IDE
was investigated using the biotin switch technique. Protein Snitrosylation is a well-recognized reversible protein modification that occurs during oxidative stress [5]. In Fig. 5, we show
that IDE is indeed nitrosylated in the presence of SNAP. When
ascorbate or HPDP-biotin were eliminated from the assay, Snitrosylated cysteine could not be switched for biotin, and the
immunoblot signal detected was very minimal, with intensity
similar to that of IDE in the absence of NO donor treatment
(Fig. 5, lanes 2, 3, and 4).

Fig. 3 – 125I-Amyloid-b degradation by IDE in the presence of IDE inhibitors and with the addition of NO Donors. (a) Ab
degradation by IDE is significantly inhibited in the presence of known IDE inhibitors at [1 T 10S4] (open bars) and
[1 T 10S3 M] (filled bars) concentrations of 1,10 phenanthroline (1,10 Phen.) and NEM, but PMSF did not have an inhibitory
effect. (b) Partially purified rat IDE enzyme was treated with NO donors (filled bars) or control compounds (open bars), at
[1 T 10S3 M] (mean W S.E.M. of at least three independent experiments). *P < 0.05, **P < 0.01.

biochemical pharmacology 77 (2009) 1064–1073
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Fig. 4 – Proteasome trypsin- and chymotrypsin-like activity with NO donor treatment. Partially purified rat IDE enzyme with
proteasome was treated with increasing concentrations of NO donor and assessed for proteasome trypsin- and
chymotrypsin-like activity using fluorogenic proteasome substrates (mean W S.E.M. of I3 independent experiments). (a)
Insulin ( ) inhibited proteasome chymotrypsin-like activity by 50% at [1 T 10S7 M]. SNAP (*) inhibited activity significantly at
[1 T 10S5 M] and [1 T 10S4 M] of compound, but the control, SNAP(ox) (~) (curve fit did not converge), did not. (b) Similar results
were seen with SNAP treatment on the proteasome trypsin-like activity. (c) SNP (&) significantly inhibited chymotrypsin-like
activity at [1 T 10S3 M]. Treatment with both SNP + ascorbate [1 T 10S3 M] (&) and KFC (^) significantly inhibited activity at
[1 T 10S5 M]. (d) Trypsin-like activity was significantly inhibited by both SNP and KFC at [1 T 10S3 M]. *P < 0.05, **P < 0.01.

We also tested, by HPLC analysis, the qualitative effect of
NO donors on the generation of insulin degradation products.
Fig. 6a shows a representative elution profile of 125I-insulin
and fragments after incubation with partially purified recom-

Fig. 5 – Protein nitrosylation of IDE with the treatment of
NO donor, SNAP. Partially purified rat IDE enzyme was
incubated and processed using the biotin switch method
(1) +SNAP [1 T 10S4 M], (2) untreated enzyme, (3) +SNAP
[1 T 10S4 M] in the absence of the biotinylating agent, (4)
+SNAP [1 T 10S4 M] but without ascorbate [1 T 10S3 M]
treatment prior to the biotinylation step. Biotinylated
proteins were removed from the samples by incubation
with Neutravidin-agarose beads, and eluted proteins
eluted were resolved by SDS-PAGE and immunoblotted
using an anti-IDE antibody. IDE was nitrosylated in the
presence of SNAP [1 T 10S4 M]. Blot is representative of
three independent experiments.

binant human IDE. Fig. 6b shows the elution profile of insulin
after incubation with the enzyme in the presence of SNAP and
SNAP(ox). All product patterns were similar, with no major
products missing, or additional peaks arising, with the
addition of the NO donors. The only effect seen was a
decrease in the production of small insulin fragments, which
indicates that the enzyme was inhibited by SNAP, but not by
the oxidized form. The same elution profiles were observed
regardless of whether rat enzyme or the recombinant human
enzyme was tested (partially purified rat enzyme data not
shown).
To further examine the nature of the inhibition of NO on
IDE, we cross-linked insulin to IDE in the presence and
absence of NO donors. Fig. 7 shows a sample autoradiograph of
the 110-kDa band (the molecular weight of IDE) and quantification by densitometry. SNAP at the highest concentration
tested [1  104 M] did not suppress insulin cross-linking, nor
did the SNAP(ox) control. We tested the effect of SNP and KFC
on IDE binding of insulin, and found that these compounds
also did not increase or decrease insulin binding to the enzyme
(data not shown). This indicates that NO inhibits insulin
degradation without disrupting insulin binding to IDE, which
is suggestive of a noncompetitive type of inhibition.
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Fig. 6 – HPLC analysis of insulin degradation products. Insulin degradation products were measured in partially purified
) and enzyme
recombinant human IDE enzyme. (a) Untreated enzyme alone (b) Enzyme treated with 1 T 10S4 M SNAP (
treated with 1 T 10S4 M SNAP(ox) (- - -). No qualitative differences were seen in the insulin degradation products produced
by any of the treatments.

Fig. 7 – Covalent crosslink of partially purified IDE enzyme
to 125I-insulin in the presence of the NO donor, SNAP. (a)
Representative autoradiograph of the effect of SNAP on
125
I-insulin binding to IDE. Lane (1) enzyme + SNAP
[1 T 10S4 M], (2) enzyme + SNAP(ox) [1 T 10S4 M], (3)
enzyme + non-radiolabeled insulin, (4)
enzyme + radiolabeled insulin, (5) no enzyme and (6)
enzyme without DSS cross-linking agent. (b)
Densitometric analysis of three independent experiments.
SNAP or control donor treatment did not significantly
affect insulin binding to IDE.

4.

Discussion

Our data show that NO can inhibit the actions of IDE toward
two IDE substrates, insulin and Ab. This inhibition has
implications in conditions such as diabetes, insulin resistance,
and Alzheimer’s disease. Increased inflammation and the
elevated production of NO have been shown to affect insulin
clearance and processing, which contributes to overall insulin

resistance [29,30]. Enhanced expression of iNOS as a result of
inflammation is a factor in insulin resistance, and depletion of
iNOS has been shown to enhance insulin sensitivity [7,8,29]. A
large body of literature has shown that inflammation and
insulin resistance may be underlying causes in the development of Alzheimer’s disease as well [31–33]. Our studies show
that NO donors noncompetitively inhibit IDE degradation of
two substrates, insulin and Ab, but that this inhibition does
not change the insulin degradation products produced, nor
does it affect IDE binding of insulin. Because IDE is responsible
for initiating insulin degradation in endosomes, impairment
of IDE degradation of insulin could contribute to decreased
clearance of insulin and thereby contribute to the hyperinsulinemia that is observed under both insulin-resistant and
diabetic conditions [34,35]. Likewise, inhibition of IDE by NO in
the brain could contribute to an accumulation of Ab, leading to
the development of insoluble fibrous plaques.
Three different NO donors were used in this study, SNP,
SNAP, and PAPA-NONOate and they each have different
mechanisms of NO donation and chemistry. SNP has been
used clinically as a NO donor and vasodilator for the treatment
of severe hypertension and cardiovascular disease, and
releases NO after reaction with reducing agents, such as
ascorbate [26]. However, the ferrocyanide moiety present in
the compound has the potential to generate cyanide and Fe(II),
which can both act as oxidizing agents [36]. In order to
differentiate the NO-attributed effects from the potential
oxidative effects of SNP, the control compound, KFC, was used.
SNP was shown to inhibit insulin degradation by IDE, and the
addition of ascorbate to the reaction increased the inhibitory
effect presumably because of the enhanced NO release from
the compound. Additionally, ascorbate has been shown to
convert S-nitrosylated cysteine residues to reduced cysteine
residues, and this could potentially result in reactivation of the
enzyme. However, the reactivating effect does not appear to be
predominant in our experiments as the presence of ascorbate
in the reaction increased the inhibitory effect of SNP. The
control compound, KFC, did not inhibit insulin degradation,
indicating that the inhibitory effects observed with SNP were
attributable to the NO being released and not to potential
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enzymatic oxidation of IDE. This same result was not observed
in the analysis of IDE-mediated regulation of the proteasome
activity. The proteasome is affected by oxidation, and that was
apparent with the addition of KFC, which is an oxidizing agent
[37,38]. However, the slopes of the inhibition curves for SNP
and KFC were different. This suggests that the inhibition of
proteasome activity by SNP and KFC were potentially operating through different mechanisms.
SNAP can directly release NO into solution by spontaneous
cleavage of its NO moiety or can nitrosylate protein thiols by
transfer of NO+ [39,40]. The rate of NO release from this
nitrosothiol compound is thought to be unaffected by
ascorbate. We found this to be the case in our experiments,
as SNAP inhibited insulin degradation by 50% with no effect on
the potency of the compound with the addition of ascorbate.
This agrees with the reported mechanism of action of SNAP
[39]. In assessing the effect of SNAP on IDE-mediated
regulation of proteasome activity, SNAP was found to inhibit
proteasome trypsin- and chymotrypsin-like activities with an
inhibition curve similar to SNAP inhibition of insulin degradation, which is indicative of NO inhibiting through a similar
mechanism. The oxidized form of SNAP did not have an effect
on the proteasome activity. These findings indicate that SNAP
inhibition of the proteasome was functioning through the
inhibition of IDE by NO in our enzyme preparation. We believe
that the binding of NO to IDE, like the binding of insulin to IDE,
results in a dissociation of IDE from the proteasome, resulting
in a decrease in proteasome peptidolytic activity [41]. When
NO levels are increased, such as in inflammation, protein
degradation could be decreased, and, more importantly, the
ability of insulin to alter protein degradation via the proteasome would be abrogated. NO inhibition of IDE may contribute
to insulin resistance by disrupting insulin-mediated control of
protein metabolism.
PAPA-NONOate spontaneously donates NO in a pHdependent, first-order process, and has a half-life of 15 min
under the assay conditions used in this study [42]. The control
compound, sulfo-NONOate, is chemically similar to PAPANONOate, but it does not release NO; it dissociates in solution
to form only sulfate and nitrous oxide (N2O) [43]. PAPANONOate showed a significant inhibitory effect on both
insulin and Ab degradation, but the control compound
sulfo-NONOate did not affect the degradation of either
substrate, indicating that the inhibition seen was likely due
to NO. The amount of NO released by PAPA-NONOate in the
assay was similar to that which was released by SNAP, or
about 100 fold less NO released than donor compound. The
inhibitory effect of PAPA-NONOate on Ab degradation was 25%
greater at 1  103 M concentration of compound than the
effect of SNAP at the same concentration. This could be
attributed to the known half-life of this compound, which is
on the order of minutes, compared to the half-life of SNAP,
which is a few hours [39,44].
SNP, SNAP, and PAPA-NONOate were not equally efficacious in inhibiting insulin and Ab degradation. This was due to
differences in NO release from the compounds. SNP required a
tenfold higher amount of donor compound to achieve the
same level of inhibition in insulin degradation that was seen
with 104 M SNAP. Even though the amount of SNP was
greater, the actual amount of NO released from the compound
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was at the micromolar level, similar to that released by SNAP
at 104 M (Table 1). The NO donors also appeared to inhibit
insulin degradation at lower concentrations relative to Ab
degradation. This effect is likely due to differences in substrate
size and substrate requirements for binding to the enzyme.
The inhibition of IDE by NO did not qualitatively change the
insulin degradation products produced, but it did decrease the
amount of the smallest products of insulin degradation. These
results suggest that NO donors do not alter IDE preference for
cleavage sites on insulin, but that NO does inhibit overall
degradation. When we examined the ability of IDE to bind
insulin in the presence of NO donors, we found that the NO
donors did not inhibit insulin binding. This suggests that the
NO donors are inhibiting IDE noncompetitively, and this was
confirmed by kinetic analysis of the inhibition. This type of
inhibition is consistent with what is known about the
structure of IDE and the location of its cysteine residues.
IDE has long been shown to be sensitive to sulfhydryl
reagents, but which of its cysteine residues was responsible had
not been known [20–22]. Neant-Fery et al. have recently shown
that cysteines C178, C812, and C819 are the residues largely
conferring thiol sensitivity [23]. Thus, these are the residues
most likely mediating the inhibitor effect of NO. Recently the
three-dimensional structure of IDE has been elucidated
revealing the spatial location of these cysteines, and demonstrating IDE to be a unique enzyme [45]. The N-terminal and Cterminal halves of the molecule form two bowl-like structures,
linked with a short intermediate peptide chain. The two halves
fit together like a clamshell, forming an interior pocket that
contains the active site and substrate binding regions. The
closed form, with the substrate buried within, appear to be the
most catalytically active. Cysteine C178 is in the N-terminal
half, and is proximate to the active site (aa 108–112). Nitrosylation of this residue could interfere with catalysis, similar to Nethylmaleimide. The authors of that paper suggest adducting
C178 could either alter the position of the active site residues, or
interfere with the interaction of the C- and N-terminal regions
(or ‘‘closing’’ the enzyme), since C178 is close to residue T825
when IDE is in the closed conformation. Similarly, C812 and
C819 are at the interface of the N- and C-terminal halves. Thus,
nitrosylation of these residues may prevent IDE from achieving
the fully closed conformation. Neant-Fery et al. suggested this
would block substrate binding, but our cross-link experiments
indicate, at least for insulin, binding still occurs. We speculate
that insulin can still associate with the enzyme in its open
conformation, but the nitrosylated cysteines at C812 and C819
prevent IDE from bringing the active site into the proper
position to catalyze hydrolysis. We cannot rule out that other
cysteines are nitrosylated and contribute to the inactivation of
IDE, but these residues seem the most likely candidates.
We have found that IDE is nitrosylated in the presence of
NO donors, and this inhibition of IDE may represent a
physiologic control mechanism for the protein. More than
100 proteins have been shown to be S-nitrosylated in vitro and
in intact cells, including proteins involved in insulin signal
transduction [46]. The concentrations of the artificial NO
donors used in this study may seem superphysiologic;
however, the amount of NO released from these compounds
is actually at least 100-fold less than the concentration of
compound used. This brings the amount of NO in these assays
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into the micromolar and sub-micromolar range, well within
the range of NO known to be released by iNOS intracellularly
[47,48]. Therefore, S-nitrosylation of IDE is a potentially
physiologically relevant mechanism of metabolic control for
the actions of IDE. These findings have important implications
for diabetes and insulin resistance, as well as Alzheimer’s
disease. Nitrosylative regulation of proteins is a complex and
not fully understood process at this time, but what is known is
that the redox state of the cell impacts the activity and
function of a large number of proteins. How this type of
protein regulation affects the cell is critical to providing a
better understanding of the pathogenesis of disease that are
affected by inflammation and nitrosative stress. Prevention of
the effects of inflammation on cellular processes could lead to
the development of novel therapeutic strategies to better treat
or even prevent the onset of debilitating diseases such as
diabetes and Alzheimer’s.
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